News
SurvivorNet on MSN2d
A Promising New Option For PIK3CA-Mutated Breast Cancer: What New Data On Inavolisib Could Mean for YouInavolisib (Itovebi) is a new targeted therapy for HR+ HER2-negative metastatic breast cancer with a PIK3CA mutation.
Research presented at the ASCO Annual Meeting 2025 highlighted new potential standards of care and other advances in breast cancer.
Trastuzumab deruxtecan with pertuzumab significantly extended progression-free survival in HER2-positive advanced breast cancer, compared to standard THP therapy, according to DESTINY-Breast09 trial ...
Dr Heather McArthur describes how ASCO 2025 showcased new standards of care in triple-negative and HER2-positive settings.
El fármaco está indicado en monoterapia para tratar a el cáncer de mama HER2 positivo no resecable y/o metastásico que hayan recibido uno o más regímenes previos anti-HER2.
In this video, Megan Kruse, MD, breast medical oncologist at Cleveland Clinic, discusses results from an interim analysis of the DESTINY-Breast09 trial, which were presented at ASCO Annual Meeting.The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback